Discovery And Development Of Therapeutics From Natural Products Against Neglected Tropical Diseases

Discovery and Development of Therapeutics from Natural Products against Neglected Tropical Diseases draws together research on medicinal agents from natural sources as starting points for the design of drugs against Neglected Tropical Diseases (NTDs). From the prediction of promising leads and identification of active agents, to the extraction of complex molecules, the book explores novel, economical and efficacious therapeutics for these diseases. It describes current research and the role of natural products, antimalarial compounds from marine natural products and sesquiterpene lactones, natural antileprotic agents, natural products with potential against Leishmaniasis, Trypanosomiasis and Dengue, and more. In addition, Quinoline and Isoquinoline alkaloids for developing new antiprotozoal agents are discussed, alongside anti-trypanosomatid heterocyclic compounds as structures for development. Combining the expertise of specialists from around the world, this volume aims to support and encourage researchers in the investigation of natural sources as starting points for the development of novel, safe and effective agents for use against neglected tropical diseases. Includes chapters written by active researchers and leading global experts deeply engaged in the research field of natural product chemistry for drug discovery Draws together cutting-edge research advances in natural product chemistry that are targeted at neglected tropical diseases Highlights the future potential of natural products as sources of novel medicinal compounds against neglected tropical diseases

A drug discovery reference to the crippling tropical diseases that affect more than 1 billion people. Neglected Tropical Diseases is the first book of its kind to offer a guide that follows the World Health Organization?s list of neglected tropical diseases. The authors?all are experts on the topic?address the development of effective treatments for 12 crippling infectious diseases that affect almost 20% of the world?s popluation. The book includes information on the common approaches and the most important factors that lead to the development of new drugs for treating tropical diseases. Individual chapters review 12 neglected tropical diseases that are grouped by infectious agent, from viruses to bacteria to eukaryotic parasites. For each of these diseases, the book explains the unmet medical need and explores the current and potential drug discovery strategies. The book also includes information on potential drug compounds derived from natural products. This important book: -Ties together information from different sources for developing novel treatsments forneglected tropical diseases -Is aligned with WHO?s initiative to eradicate tropical diseases -Outlines current and potential drugs for treating tropical diseases -Provides a standard reference for the entire field Written for medicinal chemists, pharmaceutical chemists, pharmaceutical industry, virologists, parasitologists, and specialists on tropics medicine, Neglected Tropical Diseases offers an essential guide and a systematic reference for the development of successful treatments for 12 crippling infectious diseases.

NEGLECTED TROPICAL DISEASES AND PHYTOCHEMICALS IN DRUG DISCOVERY Explore novel drug discovery updates from medicinal plants to help fight the devastating effects of neglected tropical diseases Neglected Tropical Diseases and Phytochemicals in Drug Discovery delivers a comprehensive exploration of the drug discovery process as it pertains to neglected tropical diseases. The book covers recent advancements in drug discovery, as well as druggable targets and new challenges facing the industry. It offers readers expansive discussions of specific diseases, including protozoan, helminth, bacterial, viral, fungal, and ectoparasitic infections. This book provides readers with insightful perspectives from leading industry voices on fifty years of trends and progress in the search for new, safe, and affordable therapeutic drugs in the fight against neglected tropical diseases. It includes information beneficial to researchers in a variety of fields of biology, chemistry, medicine, and pharmaceuticals. The distinguished authors cover topics including the effects of phytochemicals on the causative agent of leprosy and the potential applicability of phytochemicals in the management of Dengue fever. Readers will also enjoy the inclusion of: Thorough introductions to neglected tropical diseases, phytochemicals, protein targets, and mechanisms in drug discovery, as well as the epidemiology of neglected tropical diseases An exploration of novel bioactive lead compounds for drug discovery against neglected tropical diseases, leishmaniasis, lymphatic filariasis, trypanosomiasis, and schistosomiasis Discussions of protozoan infections, including herbal, nutritional, and traditional remedies for giardiasis and the anti-leishmanial potentials of phytochemicals Examinations of helminth infections, including the prospects of phytochemicals in the treatment of helminthiasis Perfect for medicinal chemists, drug developers, and research and development scientists, Neglected Tropical Diseases and Phytochemicals in Drug Discovery will also earn a place in the libraries of toxicologists and researchers in biology, chemistry, medicinal chemistry, ethnobotany, and bioinformatics seeking a one-stop resource for drug discovery for neglected tropical diseases.

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.

The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development because they can expect a large return on investment, organizations developing drugs to treat rare and neglected diseases are unable to rely on such returns. On June 23, 2008, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop, "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies," which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases.

"The presence, or absence, of neglected tropical diseases (NTDs) can be seen as a proxy for poverty and for the success of interventions aimed at reducing poverty. Today, coverage of the public-health interventions recommended by the World Health Organization (WHO) against NTDs may be interpreted as a proxy for universal health coverage and shared prosperity - in short, a proxy for coverage against neglect. As the world's focus shifts from development to sustainable development, from poverty eradication to shared prosperity, and from disease-specific goals to universal health coverage, control of NTDs will assume an important role towards the target of achieving universal health coverage, including individual financial risk protection. Success in overcoming NTDs is a "litmus test" for universal health coverage against NTDs in endemic countries. The first WHO report on NTDs (2010) set the scene by presenting the evidence for how these interventions had produced results. The second report (2013) assessed the progress made in deploying them and detailed the obstacles to their implementation. This third report analyses for the first time the investments needed to achieve the scale up of implementation required to achieve the targets of the WHO Roadmap on NTDs and universal coverage against NTDs. INVESTING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES presents an investment strategy for NTDs and analyses the specific investment case for prevention, control, elimination and eradication of 12 of the 17 NTDs. Such an analysis is justified following the adoption by the Sixty-sixth World Health Assembly in 2013 of resolution WHA6612 on neglected tropical diseases, which called for sufficient and predictable funding to achieve the Roadmap's targets and sustain control efforts. The report cautions, however, that it is wise investment and not investment alone that will yield success. The report registers progress and challenges and signals those that lie ahead. Climate change is expected to increase the spread of several vector-borne NTDs, notably dengue, transmission of which is directly influenced by temperature, rainfall, relative humidity and climate variability primarily through their effects on the vector. Investments in vector-borne diseases will avoid the potentially catastrophic expenditures associated with their control. The presence of NTDs will thereby signal an early warning system for climate-sensitive diseases. The ultimate goal is to deliver enhanced and equitable interventions to the most marginalized populations in the context of a changing public-health and investment landscape to ensure that all peoples affected by NTDs have an opportunity to lead healthier and wealthier lives."--Publisher's description.

Discovery and Development of Anti-Breast Cancer Agents from Natural Products presents cutting-edge research advances in the field of bioactive natural products and natural drug formulations. This volume in the Natural Products Drug Discovery series focuses on molecules of natural origin and their synthetic analogs that show promising potential to act as anti-breast cancer and chemotherapeutic agents. Combining foundational background information on cancer mechanisms with details of medicinal structures from natural products, this volume compiles the latest developments from across interdisciplinary fields. Discovery and Development of Anti-Breast Cancer Agents from Natural Products will serve as a valuable resource for researchers working to discover promising leads for the development of novel pharmaceuticals for breast cancer, highlighting a number of key structures from natural products and exploring possible future developments in the area. Highlights active agents from natural sources for development as novel anti-cancer agents Features contributions from active researchers and leading experts working in the field Includes foundational background information on both breast cancer mechanisms and natural product structures to support researchers from different disciplines

Discovery and Development of Anti-inflammatory Agents from Natural Products, the latest volume in the Natural Product Drug Discovery series, presents cutting-edge research advances in the field of bioactive natural products and natural drug formulations, with this volume focusing on molecules of natural origin and their synthetic analogues that have the potential to act against the pathogens responsible for inflammatory diseases. All aspects of each are covered, including isolations and structure elucidations, in vitro and in vivo biological activity, synthetic optimization, investigations of pharmacodynamics and kinetics, and the structure-activity relationships of anti-inflammatory natural products. Written by active researchers and leading experts, this book brings together an overview of current discoveries and trends in this field. It will be a valuable resource for researchers working to discover promising leads for the development of pharmaceuticals in the prevention and treatment of anti-inflammatory diseases. Features contributions from active researchers and leading experts working in medicinal natural products and herbal formulations Includes recent, cutting-edge advances on medicinal natural products, along with preventative therapies for different kinds of inflammation-directed diseases Offers an authoritative source of information on the industrial application of natural products for medicinal purposes